新闻
2023-06-01
融资
2023-06-01
百济神州:加拿大第四项!百悦泽获批治疗慢性淋巴细胞白血病
临床结果上市批准ASH会议
2023-06-01
亚盛医药:奥雷巴替尼第二次拟获纳入突破性治疗品种,治疗SDH缺陷型GIST
优先审批突破性疗法申请上市
2023-06-01
创新药解析 | 用于缓解慢性疼痛的“分子手术刀”
突破性疗法
2023-06-01
全球新药进展早知道 06-01
上市批准临床研究优先审批
2023-05-31
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
临床申请寡核苷酸临床1期
2023-05-31
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
免疫疗法抗体药物偶联物
2023-05-31
基因疗法引进/卖出
2023-05-31
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
上市批准临床结果
2023-05-31
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
免疫疗法